Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing

Brittny N. Tillman, Megan Yanik, Andrew C. Birkeland, Chia Jen Liu, Daniel H. Hovelson, Andi K. Cani, Nallasivam Palanisamy, Shannon Carskadon, Thomas E. Carey, Carol R. Bradford, Scott A. Tomlins, Jonathan B. McHugh, Matthew E. Spector, J. Chad Brenner

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background Targeted sequencing of patients with epidemiologically low-risk (ELR) head and neck squamous cell carcinoma (HNSCC) could help identify novel drivers or lost suppressors leading to precision medicine protocols and improved survival rates. Methods A patient with ELR-HNSCC was selected for targeted sequencing. We then assessed next generation sequencing cohorts from the Oncomine Powertool Database, which contains pan-cancer data from The Cancer Genome Atlas (TCGA). Results Targeted sequencing revealed fibroblast growth factor receptor-1 (FGFR1) amplifications as a putative driver of the patient's tumor. Patients with HNSCC from TCGA data demonstrated fibroblast growth factor (FGF) family mutations, rearrangements, or amplifications in over 35% of HNSCC cases, with a statistically significant higher frequency in African American populations. FGF alterations were unique from activating phosphatidylinositol 3-kinase (PIK3CA) mutations. Conclusion Together, these data suggest that FGF signaling may be critical for a subset of patients with HNSCC independent of other known pathways and provides rationale for leveraging patients with ELR-HNSCC to define molecular subsets of high-risk HNSCC.

Original languageEnglish (US)
Pages (from-to)E1646-E1652
JournalHead and Neck
Volume38
DOIs
StatePublished - Apr 1 2016
Externally publishedYes

Fingerprint

Fibroblast Growth Factors
Atlases
Neoplasms
Receptor, Fibroblast Growth Factor, Type 1
Phosphatidylinositol 3-Kinase
Genome
Precision Medicine
Mutation
Carcinoma, squamous cell of head and neck
African Americans
Survival Rate
Databases
Population

Keywords

  • amplification
  • fibroblast growth factor (FGF)
  • fibroblast growth factor receptor (FGFR)
  • head and neck squamous cell carcinoma (HNSCC)
  • mutant

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing. / Tillman, Brittny N.; Yanik, Megan; Birkeland, Andrew C.; Liu, Chia Jen; Hovelson, Daniel H.; Cani, Andi K.; Palanisamy, Nallasivam; Carskadon, Shannon; Carey, Thomas E.; Bradford, Carol R.; Tomlins, Scott A.; McHugh, Jonathan B.; Spector, Matthew E.; Chad Brenner, J.

In: Head and Neck, Vol. 38, 01.04.2016, p. E1646-E1652.

Research output: Contribution to journalArticle

Tillman, BN, Yanik, M, Birkeland, AC, Liu, CJ, Hovelson, DH, Cani, AK, Palanisamy, N, Carskadon, S, Carey, TE, Bradford, CR, Tomlins, SA, McHugh, JB, Spector, ME & Chad Brenner, J 2016, 'Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing', Head and Neck, vol. 38, pp. E1646-E1652. https://doi.org/10.1002/hed.24292
Tillman, Brittny N. ; Yanik, Megan ; Birkeland, Andrew C. ; Liu, Chia Jen ; Hovelson, Daniel H. ; Cani, Andi K. ; Palanisamy, Nallasivam ; Carskadon, Shannon ; Carey, Thomas E. ; Bradford, Carol R. ; Tomlins, Scott A. ; McHugh, Jonathan B. ; Spector, Matthew E. ; Chad Brenner, J. / Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing. In: Head and Neck. 2016 ; Vol. 38. pp. E1646-E1652.
@article{0966ae8a6a6b4d698396694d1c66911c,
title = "Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing",
abstract = "Background Targeted sequencing of patients with epidemiologically low-risk (ELR) head and neck squamous cell carcinoma (HNSCC) could help identify novel drivers or lost suppressors leading to precision medicine protocols and improved survival rates. Methods A patient with ELR-HNSCC was selected for targeted sequencing. We then assessed next generation sequencing cohorts from the Oncomine Powertool Database, which contains pan-cancer data from The Cancer Genome Atlas (TCGA). Results Targeted sequencing revealed fibroblast growth factor receptor-1 (FGFR1) amplifications as a putative driver of the patient's tumor. Patients with HNSCC from TCGA data demonstrated fibroblast growth factor (FGF) family mutations, rearrangements, or amplifications in over 35{\%} of HNSCC cases, with a statistically significant higher frequency in African American populations. FGF alterations were unique from activating phosphatidylinositol 3-kinase (PIK3CA) mutations. Conclusion Together, these data suggest that FGF signaling may be critical for a subset of patients with HNSCC independent of other known pathways and provides rationale for leveraging patients with ELR-HNSCC to define molecular subsets of high-risk HNSCC.",
keywords = "amplification, fibroblast growth factor (FGF), fibroblast growth factor receptor (FGFR), head and neck squamous cell carcinoma (HNSCC), mutant",
author = "Tillman, {Brittny N.} and Megan Yanik and Birkeland, {Andrew C.} and Liu, {Chia Jen} and Hovelson, {Daniel H.} and Cani, {Andi K.} and Nallasivam Palanisamy and Shannon Carskadon and Carey, {Thomas E.} and Bradford, {Carol R.} and Tomlins, {Scott A.} and McHugh, {Jonathan B.} and Spector, {Matthew E.} and {Chad Brenner}, J.",
year = "2016",
month = "4",
day = "1",
doi = "10.1002/hed.24292",
language = "English (US)",
volume = "38",
pages = "E1646--E1652",
journal = "Head and Neck Surgery",
issn = "0148-6403",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing

AU - Tillman, Brittny N.

AU - Yanik, Megan

AU - Birkeland, Andrew C.

AU - Liu, Chia Jen

AU - Hovelson, Daniel H.

AU - Cani, Andi K.

AU - Palanisamy, Nallasivam

AU - Carskadon, Shannon

AU - Carey, Thomas E.

AU - Bradford, Carol R.

AU - Tomlins, Scott A.

AU - McHugh, Jonathan B.

AU - Spector, Matthew E.

AU - Chad Brenner, J.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Background Targeted sequencing of patients with epidemiologically low-risk (ELR) head and neck squamous cell carcinoma (HNSCC) could help identify novel drivers or lost suppressors leading to precision medicine protocols and improved survival rates. Methods A patient with ELR-HNSCC was selected for targeted sequencing. We then assessed next generation sequencing cohorts from the Oncomine Powertool Database, which contains pan-cancer data from The Cancer Genome Atlas (TCGA). Results Targeted sequencing revealed fibroblast growth factor receptor-1 (FGFR1) amplifications as a putative driver of the patient's tumor. Patients with HNSCC from TCGA data demonstrated fibroblast growth factor (FGF) family mutations, rearrangements, or amplifications in over 35% of HNSCC cases, with a statistically significant higher frequency in African American populations. FGF alterations were unique from activating phosphatidylinositol 3-kinase (PIK3CA) mutations. Conclusion Together, these data suggest that FGF signaling may be critical for a subset of patients with HNSCC independent of other known pathways and provides rationale for leveraging patients with ELR-HNSCC to define molecular subsets of high-risk HNSCC.

AB - Background Targeted sequencing of patients with epidemiologically low-risk (ELR) head and neck squamous cell carcinoma (HNSCC) could help identify novel drivers or lost suppressors leading to precision medicine protocols and improved survival rates. Methods A patient with ELR-HNSCC was selected for targeted sequencing. We then assessed next generation sequencing cohorts from the Oncomine Powertool Database, which contains pan-cancer data from The Cancer Genome Atlas (TCGA). Results Targeted sequencing revealed fibroblast growth factor receptor-1 (FGFR1) amplifications as a putative driver of the patient's tumor. Patients with HNSCC from TCGA data demonstrated fibroblast growth factor (FGF) family mutations, rearrangements, or amplifications in over 35% of HNSCC cases, with a statistically significant higher frequency in African American populations. FGF alterations were unique from activating phosphatidylinositol 3-kinase (PIK3CA) mutations. Conclusion Together, these data suggest that FGF signaling may be critical for a subset of patients with HNSCC independent of other known pathways and provides rationale for leveraging patients with ELR-HNSCC to define molecular subsets of high-risk HNSCC.

KW - amplification

KW - fibroblast growth factor (FGF)

KW - fibroblast growth factor receptor (FGFR)

KW - head and neck squamous cell carcinoma (HNSCC)

KW - mutant

UR - http://www.scopus.com/inward/record.url?scp=84969254546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969254546&partnerID=8YFLogxK

U2 - 10.1002/hed.24292

DO - 10.1002/hed.24292

M3 - Article

C2 - 26849095

AN - SCOPUS:84969254546

VL - 38

SP - E1646-E1652

JO - Head and Neck Surgery

JF - Head and Neck Surgery

SN - 0148-6403

ER -